CN111956571A - 一种抗敏消炎的大麻叶日霜 - Google Patents
一种抗敏消炎的大麻叶日霜 Download PDFInfo
- Publication number
- CN111956571A CN111956571A CN202010811319.8A CN202010811319A CN111956571A CN 111956571 A CN111956571 A CN 111956571A CN 202010811319 A CN202010811319 A CN 202010811319A CN 111956571 A CN111956571 A CN 111956571A
- Authority
- CN
- China
- Prior art keywords
- extract
- percent
- sodium
- inflammation
- allergy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006071 cream Substances 0.000 title claims abstract description 18
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 16
- 230000003266 anti-allergic effect Effects 0.000 title claims abstract description 16
- 244000025254 Cannabis sativa Species 0.000 title claims abstract description 10
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 title claims abstract description 10
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 title claims abstract description 10
- 235000009120 camo Nutrition 0.000 title claims abstract description 10
- 235000005607 chanvre indien Nutrition 0.000 title claims abstract description 10
- 239000011487 hemp Substances 0.000 title claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 34
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims abstract description 22
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims abstract description 22
- 229950011318 cannabidiol Drugs 0.000 claims abstract description 22
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims abstract description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 18
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims abstract description 11
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 10
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 10
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 10
- OQILCOQZDHPEAZ-UHFFFAOYSA-N Palmitinsaeure-octylester Natural products CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- GJQLBGWSDGMZKM-UHFFFAOYSA-N ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 claims abstract description 8
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims abstract description 8
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 14
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 11
- 241000218236 Cannabis Species 0.000 claims description 9
- 239000003995 emulsifying agent Substances 0.000 claims description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 7
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 7
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 7
- 229920002125 Sokalan® Polymers 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 229960001631 carbomer Drugs 0.000 claims description 7
- 235000018597 common camellia Nutrition 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 7
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims description 7
- 229940100460 peg-100 stearate Drugs 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 6
- 240000001548 Camellia japonica Species 0.000 claims description 5
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 5
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 5
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 claims description 5
- LWBVAHQZGAKXPU-BOXHHOBZSA-M sodium;(4s)-4-amino-5-octadecoxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)[C@@H](N)CCC([O-])=O LWBVAHQZGAKXPU-BOXHHOBZSA-M 0.000 claims description 5
- 240000007817 Olea europaea Species 0.000 claims description 4
- 240000001155 Opuntia dillenii Species 0.000 claims description 4
- 235000006544 Opuntia dillenii Nutrition 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 229940042585 tocopherol acetate Drugs 0.000 claims description 4
- 239000004909 Moisturizer Substances 0.000 claims description 3
- 240000001439 Opuntia Species 0.000 claims description 3
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 claims description 3
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 3
- 239000003974 emollient agent Substances 0.000 claims description 3
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 3
- 229940107131 ginseng root Drugs 0.000 claims description 3
- 229940075529 glyceryl stearate Drugs 0.000 claims description 3
- 230000001333 moisturizer Effects 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 229940057910 shea butter Drugs 0.000 claims description 3
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 3
- 244000025272 Persea americana Species 0.000 claims description 2
- 235000008673 Persea americana Nutrition 0.000 claims description 2
- 241000246044 Sophora flavescens Species 0.000 claims description 2
- 240000004308 marijuana Species 0.000 claims 3
- 240000002948 Ophiopogon intermedius Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 230000003467 diminishing effect Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 241000219357 Cactaceae Species 0.000 abstract description 2
- 235000004727 Opuntia ficus indica Nutrition 0.000 abstract description 2
- 240000009297 Opuntia ficus-indica Species 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 abstract description 2
- 230000012010 growth Effects 0.000 abstract description 2
- 230000008105 immune reaction Effects 0.000 abstract description 2
- 239000012535 impurity Substances 0.000 abstract description 2
- 210000002569 neuron Anatomy 0.000 abstract description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 238000007920 subcutaneous administration Methods 0.000 abstract description 2
- 230000017423 tissue regeneration Effects 0.000 abstract description 2
- 230000002792 vascular Effects 0.000 abstract description 2
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 18
- 230000003750 conditioning effect Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 244000248557 Ophiopogon japonicus Species 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 229940084750 sophora flavescens root extract Drugs 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 241000209507 Camellia Species 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920002643 polyglutamic acid Polymers 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- KDHFCTLPQJQDQI-BDQAORGHSA-M sodium;(4s)-4-amino-5-octadecanoyloxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(=O)[C@@H](N)CCC([O-])=O KDHFCTLPQJQDQI-BDQAORGHSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 description 1
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229930195210 Ophiopogon Natural products 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940045898 sodium stearoyl glutamate Drugs 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种抗敏消炎的大麻叶日霜，所述日霜以100重量份计，其具体组分含量如下：水40‑80%、甘油1‑10%、辛酸/癸酸甘油三酯1‑10%、棕榈酸乙基己酯1‑10%、扭刺仙人掌茎提取物0.05‑3%、麦冬根提取物0.05‑3%、苦参根提取物0.05‑3%，发明大麻二酚CBD能够引发多种免疫反应，苦参有清除皮肤内毒素杂质的功效，其丰富的本草营养可促进受损血管神经细胞的生长和修复，恢复皮下毛细血管细胞的活性；仙人掌味淡性寒，具有行气活血，消炎解毒，排脓生肌的作用，麦冬根和海藻糖则起辅助增效作用，几者按特定配比范围搭配使用，达到即时抗敏，快速消炎的作用。
Description
技术领域
本发明涉及牙膏技术领域，尤其涉及一种抗敏消炎的大麻叶日霜。
背景技术
现代社会空气污染日趋严重，过敏性物质即过敏原，进入人体后，能使某些组织细胞释放出一系列如组胺等活性物质，而这些活性物质能导致毛细血管通透性增加、黏膜腺体分泌增多、皮肤产生红肿、瘙痒、斑块等症状，从而引发肌肤敏感或过敏，其中组胺是主要的炎症因子同时也是引起瘙痒的物质基础。瘙痒作为皮肤敏感的常见伴发症，其主要致敏原和作用途径与过敏反应相似。
所以出现了针对性的护肤品，如日霜，日霜的功能分不同的产品而言，除有修护、保湿、抗皱、紧肤的作用外，最大特色还是在于可以防御环境（如紫外线、空气污染物）对肌肤的伤害。从市售日霜的成分看，大多不会脱离日霜的防护、隔离功能，因为在这些产品中多具有SPF防晒系数，或紫外线过滤剂，适合在白天出门前使用
但是现有的日霜，没有解毒、排脓、抗敏、快速消炎的功效，因此需要一种抗敏消炎的大麻叶日霜来解决以上问题。
发明内容
基于背景技术存在的技术问题，本发明提出了一种抗敏消炎的大麻叶日霜。
本发明提出的一种抗敏消炎的大麻叶日霜，所述日霜以100重量份计，其具体组分含量如下：
水 40-80%
甘油 1-10%
辛酸/癸酸甘油三酯 1-10%
棕榈酸乙基己酯 1-10%
扭刺仙人掌茎提取物 0.05-3%
麦冬根提取物 0.05-3%
苦参根提取物 0.05-3%
海藻糖 0.1-6%
鲸蜡硬脂醇 0.2-2%
硬脂酰谷氨酸钠 0.2-2%
蔗糖多油酸酯 0.2-2%
油橄榄果油 0.5-3%
牛油果树果脂 0.5-3%
山茶籽油 0.5-3%
PEG-100 硬脂酸酯 0.2-2%
甘油硬脂酸酯 0.2-2%
聚谷氨酸钠 0.05-0.2%
辛酰羟肟酸 0.05-0.2%
对羟基苯乙酮 0.1-1%
生育酚乙酸酯 0.1-1%
卡波姆 0.1-0.5%
透明质酸钠 0.05-0.2%
大麻叶提取物 0.05-5%
香精 0.05-0.5%
氢氧化钠 0.01-0.2%。
优选的，所述水作为溶剂；所述甘油、聚谷氨酸钠和透明质酸钠作为保湿剂；所述辛酸/癸酸甘油三酯、棕榈酸乙基己酯、油橄榄果油、牛油果树果脂和山茶籽油作为润肤剂；所述扭刺仙人掌茎提取物、麦冬根提取物、苦参根提取物、海藻糖、辛酰羟肟酸、对羟基苯乙酮、生育酚乙酸酯和大麻叶提取物作为皮肤调理剂；所述鲸蜡硬脂醇、硬脂酰谷氨酸钠、蔗糖多油酸酯、PEG-100 硬脂酸酯和甘油硬脂酸酯作为乳化剂；所述卡波姆作为增稠剂；所述香精作为芳香剂；所述氢氧化钠作为中和剂；所述大麻叶提取物包括大麻二酚CBD。
本发明中的有益效果为：本发明大麻二酚CBD能够引发多种免疫反应，苦参有清除皮肤内毒素杂质的功效，其丰富的本草营养可促进受损血管神经细胞的生长和修复，恢复皮下毛细血管细胞的活性；仙人掌味淡性寒，具有行气活血，消炎解毒，排脓生肌的作用，麦冬根和海藻糖则起辅助增效作用，几者按特定配比范围搭配使用，达到即时抗敏，快速消炎的作用。
具体实施方式
下面将结合本发明实施例，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。
实施例1
一种抗敏消炎的大麻叶日霜，所述日霜以100重量份计，其具体组分含量如下：
水 74.7%
甘油 5%
辛酸/癸酸甘油三酯 5%
棕榈酸乙基己酯 3%
扭刺仙人掌茎提取物 0.1%
麦冬根提取物 0.1%
苦参根提取物 0.1%
海藻糖 0.2%
鲸蜡硬脂醇 1%
硬脂酰谷氨酸钠 1%
蔗糖多油酸酯 1%
油橄榄果油 2%
牛油果树果脂 2%
山茶籽油 2%
PEG-100 硬脂酸酯 0.5%
甘油硬脂酸酯 0.5%
聚谷氨酸钠 0.1%
辛酰羟肟酸 0.1%
对羟基苯乙酮 0.2%
生育酚乙酸酯 0.5%
卡波姆 0.4%
透明质酸钠 0.1%
大麻叶提取物 0.1%
香精 0.1%
氢氧化钠 0.1%。
所述水作为溶剂；所述甘油、聚谷氨酸钠和透明质酸钠作为保湿剂；所述辛酸/癸酸甘油三酯、棕榈酸乙基己酯、油橄榄果油、牛油果树果脂和山茶籽油作为润肤剂；所述扭刺仙人掌茎提取物、麦冬根提取物、苦参根提取物、海藻糖、辛酰羟肟酸、对羟基苯乙酮、生育酚乙酸酯和大麻叶提取物作为皮肤调理剂；所述鲸蜡硬脂醇、硬脂酰谷氨酸钠、蔗糖多油酸酯、PEG-100 硬脂酸酯和甘油硬脂酸酯作为乳化剂；所述卡波姆作为增稠剂；所述香精作为芳香剂；所述氢氧化钠作为中和剂；所述大麻叶提取物包括大麻二酚CBD。
我们选取10人做使用本发明中的面膜液的实验，下表为使用10天、20天、30天、60
天后的数据以及效果：
| 序号 | 10天 | 20天 | 30天 | 60天 |
| 1 | ++ | + | ++ | +++ |
| 2 | ++ | + | ++ | ++ |
| 3 | - | + | ++ | +++ |
| 4 | + | + | ++ | ++ |
| 5 | + | ++ | ++ | ++ |
| 6 | - | ++ | +++ | +++ |
| 7 | - | ++ | ++ | +++ |
| 8 | ++ | ++ | ++ | +++ |
| 9 | ++ | ++ | ++ | +++ |
| 10 | + | ++ | ++ | +++ |
实验数据对照表1
注：（-表示效果一般：+表示效果明显：++表示效果很好；+++表示效果非常好。）
由实验数据对照表1可知，大部分用户使用了本发明的面膜液后效果明显，使用60天后，效果十分显著。
表2为一种抗敏消炎的大麻叶日霜的成分含量，具体如下：
| 标准中文名称 | 含量范围(%) | 含量(%) | 使用目的 |
| 水 | 40-80 | 74.7 | 溶剂 |
| 甘油 | 1-10 | 5 | 保湿剂 |
| 辛酸/癸酸甘油三酯 | 1-10 | 5 | 润肤剂 |
| 棕榈酸乙基己酯 | 1-10 | 3 | 润肤剂 |
| 扭刺仙人掌茎提取物 | 0.05-3 | 0.1 | 皮肤调理剂 |
| 麦冬根提取物 | 0.05-3 | 0.1 | 皮肤调理剂 |
| 苦参根提取物 | 0.05-3 | 0.1 | 皮肤调理剂 |
| 海藻糖 | 0.1-6 | 0.2 | 皮肤调理剂 |
| 鲸蜡硬脂醇 | 0.2-2 | 1 | 乳化剂 |
| 硬脂酰谷氨酸钠 | 0.2-2 | 1 | 乳化剂 |
| 蔗糖多油酸酯 | 0.2-2 | 1 | 乳化剂 |
| 油橄榄果油 | 0.5-3 | 2 | 润肤剂 |
| 牛油果树果脂 | 0.5-3 | 2 | 润肤剂 |
| 山茶籽油 | 0.5-3 | 2 | 润肤剂 |
| PEG-100 硬脂酸酯 | 0.2-2 | 0.5 | 乳化剂 |
| 甘油硬脂酸酯 | 0.2-2 | 0.5 | 乳化剂 |
| 聚谷氨酸钠 | 0.05-0.2 | 0.1 | 保湿剂 |
| 辛酰羟肟酸 | 0.05-0.2 | 0.1 | 皮肤调理剂 |
| 对羟基苯乙酮 | 0.1-1 | 0.2 | 皮肤调理剂 |
| 生育酚乙酸酯 | 0.1-1 | 0.5 | 皮肤调理剂 |
| 卡波姆 | 0.1-0.5 | 0.4 | 增稠剂 |
| 透明质酸钠 | 0.05-0.2 | 0.1 | 保湿剂 |
| 大麻叶提取物 | 0.05-5 | 0.1 | 皮肤调理剂 |
| 香精 | 0.05-0.5 | 0.1 | 芳香剂 |
| 氢氧化钠 | 0.01-0.2 | 0.1 | 中和剂 |
表2
大麻二酚 CBD，大麻中主要化学成分之一，不具有精神活性，在日用品中抗敏、消炎、抗氧化、保湿、美白、镇痛、促进睡眠等诸多方面具有突出表现。
大麻二酚CBD与通常位于免疫细胞内部的CB2受体相互作用。通过激活这些受体，大麻二酚CBD能够引发多种免疫反应，以此实现有效抚慰肌肤，消除各种肌肤敏感性反应。大麻二酚 CBD加入护肤类化妆品中，与其它原料配伍性佳，对炎症肌肤有较好的修复作用。大麻二酚CBD分子量低，与人体亲和力强。开发有效抗敏消炎的产品，与人体相容性好，有超强的抚慰皮肤功能，使用后可以快速解决皮肤日常防护、炎症等问题。为大麻二酚原料在化妆品中的应用技术提升有积极推进作用，为国产化妆品研发整体水平的提升有重要战略意义。
本发明的大麻二酚 CBD与扭刺仙人掌茎提取物、麦冬根提取物、苦参根提取物、海藻糖等植物提取物通过特定的比例进行配伍增效，采用吸收迅速的日霜配方体系，有效提升产品的抗敏消炎特性，达到即用即见效的效果。
以上所述，仅为本发明较佳的具体实施方式，但本发明的保护范围并不局限于此，任何熟悉本技术领域的技术人员在本发明揭露的技术范围内，根据本发明的技术方案及其发明构思加以等同替换或改变，都应涵盖在本发明的保护范围之内。
Claims (2)
1.一种抗敏消炎的大麻叶日霜，其特征在于，所述日霜以100重量份计，其具体组分含量如下：
水 40-80%
甘油 1-10%
辛酸/癸酸甘油三酯 1-10%
棕榈酸乙基己酯 1-10%
扭刺仙人掌茎提取物 0.05-3%
麦冬根提取物 0.05-3%
苦参根提取物 0.05-3%
海藻糖 0.1-6%
鲸蜡硬脂醇 0.2-2%
硬脂酰谷氨酸钠 0.2-2%
蔗糖多油酸酯 0.2-2%
油橄榄果油 0.5-3%
牛油果树果脂 0.5-3%
山茶籽油 0.5-3%
PEG-100 硬脂酸酯 0.2-2%
甘油硬脂酸酯 0.2-2%
聚谷氨酸钠 0.05-0.2%
辛酰羟肟酸 0.05-0.2%
对羟基苯乙酮 0.1-1%
生育酚乙酸酯 0.1-1%
卡波姆 0.1-0.5%
透明质酸钠 0.05-0.2%
大麻叶提取物 0.05-5%
香精 0.05-0.5%
氢氧化钠 0.01-0.2%。
2.根据权利要求1所述的一种抗敏消炎的大麻叶日霜，其特征在于，所述水作为溶剂；所述甘油、聚谷氨酸钠和透明质酸钠作为保湿剂；所述辛酸/癸酸甘油三酯、棕榈酸乙基己酯、油橄榄果油、牛油果树果脂和山茶籽油作为润肤剂；所述扭刺仙人掌茎提取物、麦冬根提取物、苦参根提取物、海藻糖、辛酰羟肟酸、对羟基苯乙酮、生育酚乙酸酯和大麻叶提取物作为皮肤调理剂；所述鲸蜡硬脂醇、硬脂酰谷氨酸钠、蔗糖多油酸酯、PEG-100 硬脂酸酯和甘油硬脂酸酯作为乳化剂；所述卡波姆作为增稠剂；所述香精作为芳香剂；所述氢氧化钠作为中和剂；所述大麻叶提取物包括大麻二酚CBD。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010811319.8A CN111956571A (zh) | 2020-08-13 | 2020-08-13 | 一种抗敏消炎的大麻叶日霜 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010811319.8A CN111956571A (zh) | 2020-08-13 | 2020-08-13 | 一种抗敏消炎的大麻叶日霜 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111956571A true CN111956571A (zh) | 2020-11-20 |
Family
ID=73365924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010811319.8A Pending CN111956571A (zh) | 2020-08-13 | 2020-08-13 | 一种抗敏消炎的大麻叶日霜 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111956571A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114129498A (zh) * | 2021-12-17 | 2022-03-04 | 南昌大学第一附属医院 | 一种辅助抑菌消炎精华液的加工方法 |
| WO2022266767A1 (en) * | 2021-06-23 | 2022-12-29 | London Pharmaceuticals And Research Corporation | Cannabinoid-containing formula for skin care |
-
2020
- 2020-08-13 CN CN202010811319.8A patent/CN111956571A/zh active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022266767A1 (en) * | 2021-06-23 | 2022-12-29 | London Pharmaceuticals And Research Corporation | Cannabinoid-containing formula for skin care |
| CN114129498A (zh) * | 2021-12-17 | 2022-03-04 | 南昌大学第一附属医院 | 一种辅助抑菌消炎精华液的加工方法 |
| CN114129498B (zh) * | 2021-12-17 | 2023-12-22 | 南昌大学第一附属医院 | 一种辅助抑菌消炎精华液的加工方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110693756A (zh) | 深层保湿组合物及其应用、深层保湿面膜 | |
| CN109010115A (zh) | 一种具有抗炎功效的舒敏乳霜 | |
| CN111529413A (zh) | 一种烟酰胺胶囊面膜及其制备和使用方法 | |
| CN111956571A (zh) | 一种抗敏消炎的大麻叶日霜 | |
| CN109044941B (zh) | 一种皮肤紧致滋养保湿组合物及其制备方法和应用 | |
| CN111529450A (zh) | 深层补水修复组合物，其护肤品及制备方法 | |
| CN106619358A (zh) | 一种具有舒缓抗敏修复作用的护肤制剂 | |
| CN112472653A (zh) | 一种祛痘芦荟胶及其制备方法 | |
| CN113143833A (zh) | 一种护肤品及其制备方法 | |
| CN112842943A (zh) | 一种止痒保湿修护肌肤的乳霜及其制备方法 | |
| CN113509408A (zh) | 一种护肤复合精华油 | |
| CN106420536A (zh) | 一种水凝霜及其制备方法 | |
| CN111956573A (zh) | 一种婴儿水分霜及其制备方法 | |
| CN109498523B (zh) | 一种防皲裂护肤品及其制备 | |
| KR20110016611A (ko) | 아토피 피부 개선용 조성물 및 이의 제조방법 | |
| CN111973501A (zh) | 一种神经酰胺赋活乳及其制备方法 | |
| CN112137922A (zh) | 一种去黑眼圈抗敏消炎的工业大麻叶眼霜 | |
| CN114042027A (zh) | 一种具有敏感肌修护功效的组合物及其制备方法和应用 | |
| CN112402308A (zh) | 一种多效舒缓保湿水及其制备方法 | |
| CN111494270A (zh) | 一种多效舒缓精华组合物与多效舒缓精华露及其制备方法 | |
| CN111228154A (zh) | 一种婴儿小麦鲜萃原浆乳及其制备方法 | |
| CN107184492B (zh) | 保健牙膏及其制备方法 | |
| CN112245324B (zh) | 一种具有保湿功能的化妆品及其制备方法和用途 | |
| CN113171330A (zh) | 一种檀香面膜及其制备方法 | |
| CN110013462B (zh) | 一种用于美白护肤的艾草泥膏及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201120 |